Varenicline .5 mg/1 (Varenicline TABLET, FILM COATED) .5 mg/1

Varenicline .5 mg/1 is a medication designed to aid in smoking cessation. This oral tablet helps reduce cravings and withdrawal symptoms associated with quitting smoking.

Strength

.5 mg/1

Pack Size

56 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-5089-73)

Manufacturer / TM Owner

Mylan Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Varenicline .5 mg/1 is primarily used to help individuals quit smoking. It works by targeting nicotine receptors in the brain, which can help reduce the urge to smoke. This medication is often part of a comprehensive smoking cessation plan that may include behavioral therapy and support.

Side Effects

Common effects of Varenicline .5 mg/1 may include nausea, headache, and insomnia. Some users may also experience changes in taste or vivid dreams. These effects vary among individuals and typically subside as the body adjusts to the medication.

Precautions & Warnings

Varenicline .5 mg/1 should be used with caution in individuals with a history of mental health conditions, as it may increase the risk of certain psychiatric symptoms. It is important to follow the advice of a healthcare provider regarding its use, especially for those with pre-existing medical conditions.

Avoid Interactions

Varenicline .5 mg/1 may interact with certain medications, including those metabolized by the liver's CYP2D6 enzyme. It is advisable to inform a healthcare provider about all current medications before starting Varenicline. Alcohol consumption should also be discussed, as it may affect the efficacy and safety of the medication.

Frequently Asked Questions

Varenicline .5 mg/1 is used to help individuals quit smoking by reducing cravings and withdrawal symptoms.

Varenicline .5 mg/1 is taken orally, typically once daily, as part of a smoking cessation plan.

Common side effects may include nausea, headache, and insomnia, which usually subside as the body adjusts to the medication.

Varenicline .5 mg/1 may interact with certain medications, so it is important to consult a healthcare provider before combining it with other treatments.

Varenicline .5 mg/1 should be used with caution in individuals with a history of mental health conditions and under the guidance of a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.